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Abstract
Background: Microarray normalizations typically apply methods that assume absence of global transcript shifts,
or absence of changes in internal control features such as housekeeping genes. These normalization approaches
are not appropriate for focused arrays with small sets of genes where a large portion may be expected to change.
Furthermore, many microarrays lack control features that can be used for quality assurance (QA). Here, we
describe a novel external control series integrated with a design feature that addresses the above issues.
Results: An EC dilution series that involves spike-in of a single concentration of the A. thaliana chlorophyll
synthase gene to hybridize against spotted dilutions (0.000015 to 100 µM) of a single complimentary
oligonucleotide representing the gene was developed. The EC series is printed in duplicate within each subgrid of
the microarray and covers the full range of signal intensities from background to saturation. The design and
placement of the series allows for QA examination of frequently encountered problems in hybridization (e.g.,
uneven hybridizations) and printing (e.g., cross-spot contamination). Additionally, we demonstrate that the series
can be integrated with a LOWESS normalization to improve the detection of differential gene expression
(improved sensitivity and predictivity) over LOWESS normalization on its own.
Conclusion: The quality of microarray experiments and the normalization methods used affect the ability to
measure accurate changes in gene expression. Novel methods are required for normalization of small focused
microarrays, and for incorporating measures of performance and quality. We demonstrate that dilution of
oligonucleotides on the microarray itself provides an innovative approach allowing the full dynamic range of the
scanner to be covered with a single gene spike-in. The dilution series can be used in a composite normalization
to improve detection of differential gene expression and to provide quality control measures.
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Background
High-density genomic tools, such as DNA microarrays,
provide an important opportunity to study the global
response of genomes to particular stressors or conditions.
Unfortunately, commercially-available DNA microarrays
exhibit several disadvantages when applied to toxicologi-
cal investigations. For example, in toxicology, the lack of
representation of toxicologically-relevant genes on com-
mercial microarrays is an important problem. Statistical
issues arising from existing commercial array designs
present additional limitations for toxicogenomics experi-
ments. On high-density commercial arrays, the thousands
of genes that are not involved in toxic response pathways
may remain relatively stable across exposures, thereby
weakening the statistical power necessary to identify
responsive elements of the genome [1]. Conversely,
focused arrays that contain a limited number of features
associated with particular biochemical pathways often
lack technical and biological control features, such as gene
replicates, quality assurance controls and/or normaliza-
tion features, that are required for experiments in which a
large proportion of genes may exhibit differential expres-
sion. A final impediment of commercial arrays in applica-
tions such as toxicogenomics is their high cost, which
hinders the ability to conduct experiments with sufficient
numbers of biological samples/replicates. As a result, the
use of custom-made focused microarrays has become a
popular alternative, allowing the study of genes relevant
to a specific hypothesis.
To address the limitations of commercial arrays in toxi-
cogenomics investigations, we have developed a custom
mouse oligonucleotide microarray, the HC ToxArray™,
which, by virtue of including genes that respond to a vari-
ety of chemical and physical stressors, is more relevant for
toxicological studies. Furthermore, we have incorporated
an extensive series of controls useful for both quality con-
trol and normalization of small focused arrays. Typical
microarray analyses rely on normalization methods that
assume absence of global transcript shifts, or that use
internal control features such as housekeeping genes (e.g.,
[2]). These normalization approaches are not appropriate
for focused arrays with small sets of genes [3,4]. Global
unbalanced changes are expected due to small array size
and gene selection based on pathways predicted to be
involved in a particular response. Furthermore, chemical
exposures or other parameters (e.g., phase of growth,
developmental stage, tissue, disease, etc.) may affect the
stability of housekeeping gene expression [5,6]. Therefore,
innovative normalization methods are required for these
focused arrays (e.g.,)[4,7-9]). The issue of performance
measures and quality control standards must be
addressed if microarrays are to be applied as tools in reg-
ulatory toxicology and risk assessment.
In this study, we describe novel array design features that
address the above issues. Specially positioned internal
and external control (EC) series on ToxArray™ were devel-
oped and characterized in order to eliminate the effects of
these biological variables as well as reduce additional
technical sources of variability, including uneven hybridi-
zation artifacts, minimal spot replication and print tip car-
ryover. Sensitivity of the array spots to low-abundance
RNA species was also estimated. Validation of the EC
series for normalization and comparison with another
common normalization strategy was achieved by deter-
mining the gene expression profile in mouse liver samples
following treatment with the hepatotoxin phenobarbital.
Results
Description and positioning of control spots
We developed an external control (EC) dilution series
using the Arabidopsis thaliana chlorophyll synthase gene
that involves spike-in of a single concentration of the
chlorophyll synthase cRNA to hybridize against spotted
dilutions (0.000015 to 100 µM) of a single oligonucle-
otide representing the gene within each sub-grid of the
ToxArray™ (Figure 1 and 2; see Methods). Spots of the EC
dilutions series were printed in duplicate and in some
cases in triplicate. Random dilutions from the series were
printed in an evenly spaced pattern within each subgrid,
among the oligonucleotide spots representing mouse
genes. Several negative control spots, including a random
70 mer pool and randomized hexamers, were included to
assess non-specific hybridization. A specific pattern of
buffer spots was positioned to allow calculation of cross-
spot carryover during printing.
Evaluation of background, cross-hybridization, signal 
intensity range and concentration dependence for 
ToxArray™ external control features
A BLASTN search of the 70 base oligonucleotide sequence
across GENBANK, EMBL, PDB and DDBJ sequence repos-
itories showed significant homologies only with Arabidop-
sis thaliana,  Oryza sativa and  Zea mays DNA and RNA
sequences. As expected, hybridization of Universal Mouse
Reference RNA (Stratagene) or B6C3F1 liver RNA did not
result in detectable signal from any of the EC probe dilu-
tions (data not shown). The spotted A. thaliana EC dilu-
tion series was designed to cover the full range of signal
intensities obtained with murine-specific oligonucle-
otides on the ToxArray™, from background levels to satu-
ration (Figure 3, 4). Standard deviation of the log2(Cy5/
Cy3) intensity ratios across the range of EC spike-in self vs.
self hybridization results obtained in the presence of
murine cRNA (Figure 4, black circles) was approximately
0.4 (log2), prior to normalization. In comparison to the
EC spike-in result, a much larger variance was observed in
the log2(Cy5/Cy3) intensity ratios typical of a B6C3F1
liver sample vs. Stratagene Universal Reference RNABMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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hybridization result (Figure 4, green circles). The large var-
iation in intensity ratios in the murine cRNA hybridiza-
tions were expected to occur due to widely varying
abundances of specific mRNAs within these two very dif-
ferent murine RNA sources [10].
A reciprocal dilution experiment was performed to deter-
mine the extent to which on-slide concentrations of an
oligonucleotide were mimics of the effects of variable con-
centrations of the solution-phase cRNA partner in bi-
molecular hybridization reactions and therefore suitable
for normalizing experimental variations in cRNA hybridi-
zation. Results from the on-slide dilution series were com-
pared to results from a reciprocal dilution series of the
spike-in reference cRNA made in solution. Hybridization
of the spotted dilution series with mouse RNA containing
a single spike-in concentration of the external reference
RNA produced identical profiles of signal intensities com-
Schematic of the design of one sub-grid of the ToxArray™ Figure 1
Schematic of the design of one sub-grid of the ToxArray™. Each sub-grid is printed in quadruplicate by one pin. Printing pro-
ceeds left-to-right across rows and top row to bottom row. Spot A (bottom row) represents a buffer-only negative control 
that is printed immediately following another buffer-only spot. B1 through B3 spots are 100 µM A. thaliana spots which reach 
saturation. Spots C1 through C3 are buffer-only spots that are printed immediately following B spots. The average signals from 
these spots were used to calculate the amount of cross-spot contamination (relative to Spot A) using the formula: 
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pared to the signals obtained from multiple slides hybrid-
ized with serial spike-in dilutions of the external reference
RNA (Figure 5).
Estimation of sensitivity of ToxArray™ to low-abundance 
mRNA species
The fractional sensitivity of the ToxArray™ oligonucleotide
spots was estimated from hybridizations of the serial dilu-
tions of A. thaliana cRNA into a constant amount of cRNA
(25 µg) made from the murine polyA+ mRNA, as shown
in Figure 5. The smallest fraction tested, 0.0000005 (ng A.
thaliana cRNA/ng mouse cRNA), gave significantly greater
signal intensity than background from buffer-only spots
located on the same slide (Figure 6). This level of sensitiv-
ity was greater than that necessary to detect one polyA+
mRNA molecule per cell based upon estimates of approx-
imately 300,000 mRNAs per cell [11].
Schematic of the design of one sub-grid and its relative position on a slide of the ToxArray™ Figure 2
Schematic of the design of one sub-grid and its relative position on a slide of the ToxArray™. Each sub-grid is printed in quad-
ruplicate by one pin. For example, all of the spots in sub grids numbered 1 are printed by the same pin.
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A box plot of signal intensities for each dilution of the Arabidopsis thaliana chlorophyll synthase oligonucleotide target on the  ToxArray™ is plotted for a typical single hybridization containing experiment and reference samples, each with EC spike-in Figure 3
A box plot of signal intensities for each dilution of the Arabidopsis thaliana chlorophyll synthase oligonucleotide target on the 
ToxArray™ is plotted for a typical single hybridization containing experiment and reference samples, each with EC spike-in. 
Values are raw signal intensities from all spots of each dilution, across all 48 sub-grids. Signal at the greatest dilutions reaches 
background levels (same intensities as negative controls) and saturation occurs on some spots at the 100 µM dilution.BMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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Detection of positional artifacts using the EC series
Because each individual on-slide dilution is printed two
to three times within each sub-grid, the design allows for
a simple evaluation of differential hybridization (grid to
grid) on every array. For example, in initial experiments
we detected differential hybridization from right to left
and top to bottom of our early slides (Figure 7) that was
related to the location on the slide relative to the port of
injection of hybridization solution on the automated
hybridization station. To some extent, the median of the
four widely spaced replicate subgrids would normalize
less severe systematic end-to-end and side-to-side varia-
tions in hybridization intensity that might be produced by
automated hybridization station solution injection, since
increased hybridization in one area would tend to be
compensated by decreased hybridization in another. In
the RNA profiling experiment reported in this work,
hybridization results with similar defects were excluded,
in favor of patterns with less overall difference in intensi-
ties across the slide (Figure 8).
Assessments of negative control spots and print-tip 
carryover
All three types of negative controls (buffer-only, random
70 mer oligonucleotide pools and random hexamers)
showed similar signal intensities within sub-grids indicat-
ing: 1) low background signal from the slide substrate and
printing process, and 2) that the presence of non-specific
oligonucleotides within a spot did not create hybridiza-
tion artifacts (data not shown). The amount of print-tip
carry-over of oligonucleotides from spot-to-spot during
the printing-process was determined by considering the
signal of buffer spots that were printed prior to (Spot A in
Figure 1) and immediately following the saturated signal
(Spot C1 through C3 in Figure 1) associated with the 100
µM A. thaliana oligonucleotide (Spot B in Figure 1). Per-
cent cross-spot contamination was calculated by subtract-
MA plot (log-ratio of the expression intensities versus the mean log-expression of the intensities) for a typical ToxArray™  hybridization containing a mouse liver experimental RNA sample (Cy5-labeled) and Stratagene Universal Reference RNA (Cy3- labeled), each with A thaliana spike-in control RNA added prior to labelling Figure 4
MA plot (log-ratio of the expression intensities versus the mean log-expression of the intensities) for a typical ToxArray™ 
hybridization containing a mouse liver experimental RNA sample (Cy5-labeled) and Stratagene Universal Reference RNA (Cy3-
labeled), each with A. thaliana spike-in control RNA added prior to labelling. The green circles indicate the mouse genes and 
red circles are the Rpl5 gene which reached scanner saturation in the Cy3 channel at many spots. The EC series covers the full 
range of signal intensities with no signal gaps. The LOWESS fit shown is through the external controls only, with a span of 0.3.
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ing the signal of the buffer-only spot (Spot A) from the
mean of spots printed immediately following a saturated
signal (Spots C1 though C3), divided by the mean signal
intensity of the saturated spot (Spots B1 though B3) minus
the buffer-only background (Spot A) (i.e., [C-A]/[B-A] ×
100, from Figure 1; grids are printed left to right). A plot
showing a chip with a high proportion of cross-spot con-
tamination for several print groups (groups 1, 2, 7 and 8)
is shown in Figure 9. Using this measure, the average
cross-spot contamination in the separately printed arrays
of the PB RNA profiling experiment was 0.60% (± 0.02
standard error) and 0.67% (± 0.02 standard error) for Cy5
and Cy3 respectively.
Two additional estimations of carryover artifact amount
and frequency could be made from other spot juxtaposi-
tions existing within each subgrid. In the first case, three
50 µM spots were printed prior to three random-70 mer
oligonucleotide pool spots. This situation was directly
comparable to most of the oligonucleotides representing
murine genes, in that carryover from the first spot would
be deposited into the following 40 µM spot, rather than
buffer. Among arrays employed in the PB experiment
described below, we found that the frequency of pins dis-
playing carryover from 50 µM EC spots into the 70 mer
pool spots was less (by 2 to 3-fold on a per-pin basis) than
the estimate from the 100 µM spot analysis. By design,
both 100 µM spots and the 50 µM EC spots gave hybridi-
zation signals that were near to, or fully saturated, thus
Comparison of effects of dilution of A. thaliana spike-in reference RNA in solution (target) and dilution of on-chip, spotted ref- erence oligonucleotide (probe) in mouse cRNA hybridization reactions. Background-subtracted signal intensities are plotted  against relative solution cRNA or attached oligonucleotide spot concentrations Figure 5
Comparison of effects of dilution of A. thaliana spike-in reference RNA in solution (target) and dilution of on-chip, spotted ref-
erence oligonucleotide (probe) in mouse cRNA hybridization reactions. Background-subtracted signal intensities are plotted 
against relative solution cRNA or attached oligonucleotide spot concentrations. Several murine genes with a range of expres-
sion levels were employed for slide-to-slide normalization of the spike-in RNA dilution series hybridization results.
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providing optimal levels of signal to determine carryover.
There was also a single RpL5 spot printed ahead of a buffer
spot in each grid. RpL 5 usually also had very high signal
levels that approached or reached signal saturation in
most hybridizations, allowing another independent esti-
mation of carryover. Only a single pin displayed carryover
in the PB experiment. When measured with the 100 and
50 µM EC spots and RpL5 spot described above, that pin
produced 2/3, 2/3, 0/1 individual spots with significant
carryover (greater than 0.5% of signal), respectively.
Comparison of Two Normalization Procedures for 
Detection of Differential Gene Expression using 
ToxArray™ and RT-PCR Validation of Presumptive 
Differential Gene Expression
Male B6C3F1 mice were given oral doses of 100, 10, 1 and
0.1 mg/kg PB or solvent control. Cy-labeled liver cRNA
was hybridized against mouse reference cRNA (Strata-
gene), and MAANOVA was used to examine whether the
ToxArray™ could detect both expected and novel differen-
tial expression resulting from PB exposure. The first anal-
ysis employed a composite LOWESS normalization of
microarray intensity values. This approach calculated a
LOWESS normalization of the median values of all data in
each print-tip group in addition to a LOWESS normaliza-
tion of the chip EC titration series. A normalization con-
stant that combined these two into an intensity-
dependent, weighted average was used [8]. We found a
total of 35 genes that were differentially expressed (p <
0.05 using the James-Stein Shrinkage F-Test [12] adjusted
for the False Discovery Rate (FDR); Table 1) with respect
to the overall treatment effect. These p-values obtained
from the Fs-Statistic were estimated using 1000 permuta-
tions with residual shuffling. Pairwise comparisons
showed that 16 of these genes expressed differential abun-
dances of RNA at the highest dose of PB (100 mg/kg),
while 4 were found to be differential at the 10 mg/ml
dose. No genes were identified as differentially expressed
in pairwise comparisons at the 1 mg/kg dose, nor at the
lowest dose (0.1 mg/kg, not shown).
The 16 genes with significant pairwise comparisons after
EC normalization were analysed for possible print-tip car-
ryover artifacts, since in the array batch used in the exper-
Low abundance sensitivity of the ToxArray™ at the two lowest fractions of A. thaliana cRNA in 25 µg of murine cRNA (from  dilution data shown in figure 4, above) (p values from t-tests of normalized intensities of A. thaliana oligonucleotide and buffer  spots) Figure 6
Low abundance sensitivity of the ToxArray™ at the two lowest fractions of A. thaliana cRNA in 25 µg of murine cRNA (from 
dilution data shown in figure 4, above) (p values from t-tests of normalized intensities of A. thaliana oligonucleotide and buffer 
spots). Array-to-array intensities of 40 µM A. thaliana spots were normalized to averaged signal from 72 buffer spots, 72 rand-
omized 70 mers, 8 random hexamer spots (40 µM) and eight 40 µM spots of each of three murine genes with raw intensities 
near that of 40 µM A. thaliana spots distributed on each array.
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Detection of uneven hybridization using the EC series Figure 7
Detection of uneven hybridization using the EC series. An example of the use of external controls for detection of differential 
hybridization related to the location on the slide relative to the port of injection of hybridization solution on the automated 
station. (i) The signal intensity of the 100 µM external control is plotted as a function of sub-grid number. Sub-grids are 
ordered in metacolumns of 4. The higher the sub-grid number, the closer the sub-grid is to the bottom of the slide. Two arrays 
are plotted. In the automated hybridization station, probe is injected at the top right of each slide (ii). In Array 1, it is noted 
that the first point dips for every metacolumn, indicating that sub-grids on the left hand side of the slide had lower signal inten-
sities than sub-grids on the right hand side of the slide. Similarly, the sub-grids at the bottom of the slide have lower signal 
intensity than sub-grids at the top of the slide. In Array 2, the pattern of differential hybridization from the top to the bottom 
of the slide still exists, but the positional effect is more subtle and therefore would not be detected by visualization of a slide 
without appropriate controls. These decreasing signal intensities may result from scanner output variables (e.g., photobleaching 
or optical focus as slide is scanned from top to bottom), in addition to differential hybridization.
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iment, one of the twelve printing pins had produced
carryover effects (see previous section). Four of the 16
genes were located within the suspect print group; how-
ever, none of the four oligonucleotides were printed in
positions likely to have been affected by carryover effects,
such as locations following a differential gene or a gene
with very high relative expression.
In a second analysis of the same data, using a standard
LOWESS without incorporating the ECs, 39 genes were
statistically significant (p < 0.05) after a FDR adjustment
based on the James-Stein estimator (Table 2). Between the
two analyses, there were 24 genes that were in common
(rows with bold text in Table 2), 11 genes specific to the
EC-normalized analysis and 15 specific to the LOWESS
normalized analysis (none were affected by carryover arti-
facts).
To select a sub-set of genes for RT-PCR analysis, microar-
ray gene expression data normalized with EC and without
EC (Tables 1, 2) were sorted according to the FDR
adjusted P-values. A list of genes for each type of normal-
ization was derived, in which p-values less than 0.05 were
recorded for the FDR adjusted overall treatment effect
AND for one of the pairwise comparisons, comparing the
treated samples to the control. The union of the two lists
consisted of 27 probes, with a total of 31 pairwise com-
parisons. Two additional probes (Anpep, Cyp2a4; giving
four additional pairwise comparisons) were also
included, since earlier statistical calculations (1000 per-
mutations with residual shuffling) had indicated both sig-
nificant pairwise comparisons and overall effects, but
these values were not confirmed in the analyses presented
in Tables 1 and 2. Results from the microarrays for these
35 overall and pairwise comparisons plus the results from
RT-PCR analyses for 27 of these comparisons are pre-
sented in Table 3.
The RT-PCR analyses included all 19 pairwise compari-
sons from the two microarray normalizations that gave
conflicting conclusions on whether the respective 17
probes detected differentially expressed mRNAs (Table 3).
An example of a more typical EC positional hybridization pattern Figure 8
An example of a more typical EC positional hybridization pattern. The array data were derived from a hybridization reaction of 
one RNA sample included in the EC-normalization validation exercise summarized in Tables 1–3. Cy5 (experiment) and Cy3 
(reference) values are plotted for two EC spot concentrations (6.25 and 50 µM) across the 48 subgrids on the array and 
ordered as shown in Figure 7. A comparison of the average of the Cy5/Cy3 ratios of Grids #10–28 with the combined average 
of Grids # 1–9 and 11–48 showed no significant difference (t-test, two-tailed, p = 0.390 and p = 0.393 for 50 and 6.25 µM, 
respectively)
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Based on these 19 comparisons, the results from the nor-
malization using the composite LOWESS (with EC)
revealed 15 comparisons that were in agreement with the
RT-PCR results, compared to 6 out of 19 based on the
results from LOWESS normalized data. Additional RT-
PCR analyses were done using RNA samples which gave
microarray results (6 probes with 8 pairwise comparisons)
that were in agreement between the EC and without EC
analyses (Table 3). All six microarray probe results were
confirmed to be correct, although two pairwise compari-
sons for two of the probes conflicted with the RT-PCR
results. Results from the RT-PCR were used to determine
the true positives, false negatives, false positives and true
negatives, and to calculate the sensitivity, specificity and
the efficiency of the normalization methods (Tables 4 and
5). Using the EC series (composite normalization) yielded
higher sensitivity, specificity and efficiency compared to
not using the EC series for normalization, considering
either all pairwise comparisons or just those in disagree-
ment.
Two Chi-square contingency table analyses comparing the
results from the RT-PCR and the results from both micro-
array analyses were conducted. Only the 19 probes that
were in disagreement between the two microarray results
were included and a Yates correction (a continuity correc-
tion) was applied. The RT-PCR and the results from the
composite LOWESS indicated an association with a p-
value of 0.0485, whereas RT-PCR and the results from the
LOWESS normalized data without the external controls
showed no association (p-value = 0.2301).
Effect of Spot Replication on Detection of Differential 
Gene Expression using ToxArray™
The effect of spot replication (spots arranged in 4 replicate
supergrids, per array) on the power of ToxArray™ to detect
differences in expression was estimated by conducting the
EC-based and LOWESS-based normalizations, using one
randomly chosen spot per array. The number of genes
identified as significantly differentially expressed was
reduced in the single-spot analysis to 13 and 16 genes
revealed by EC and LOWESS normalization, respectively,
compared to 35 and 39, respectively, by the 4-spot analy-
sis. Only eight of the 24 genes identified in common in
the 4-spot analysis were also identified in common in the
single spot analyses (Cyp2b10, Cyp2b9, Gstm3, Gdf15,
Detection of cross-spot contamination (in %) per pin across a ToxArray™ slide Figure 9
Detection of cross-spot contamination (in %) per pin across a ToxArray™ slide. The slide was hybridized with Cy5-labeled 
mouse liver RNA and with Cy3-labeled Universal mouse reference RNA. The slide shows a high amount of cross-pin carry-
over from the 100 µM EC oligonucleotide to the buffer spot in both the Cy3 and Cy5 channels. Cross-pin carry-over is noted 
in all sub-grids printed by pin 7.
%
(Pin/Grid)
%
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Table 1: ToxArray™ data normalized using EC: Overall adjusted p after exposure to PB and fold changes (relative to Control) and 
pairwise p-values at each dose for each gene (probe) that showed differential expression.
Control versus 
100 mg/kg
Control versus 
10 mg/kg
Control versus 
1 mg/kg
James-Stein 
F-Test †
Gene(probe) 
Name>
Full name GenBank Fold 
change
Pairwise 
P-value
Fold 
change
Pairwise 
P-value
Fold 
change
Pairwise 
P-value
Overall 
P-value
Cyp2b9 cytochrome P450, 2b9, 
phenobarbitol inducible, type a,
NM_010000 8.29 0.0000 3.22 0.0000 1.16 0.8087 0.0000
Cyp2b10 Cytochrome P450, 2b10, 
phenobarbitol inducible, type b
NM_009998 5.10 0.0000 2.95 0.0000 -1.08 0.8437 0.0000
Gdf15 growth differentiation factor 15 NM_011819 2.83 0.0000 1.25 0.3499 1.07 0.8667 0.0000
Gstm3 glutathione S- transferase mu 3 
(EC 2.5.1.18)
J03953 2.16 0.0000 1.04 0.8458 1.30 0.4200 0.0000
Lpin1 lipin 1, alias fatty liver dystrophy NM_015763 -1.94 0.0009 -1.18 0.3932 -1.08 0.8437 0.0039
Gadd45b growth arrest and DNA-damage-
inducible 45 beta
NM_008655 1.92 0.0000 1.08 0.6595 -1.13 0.7038 0.0000
Gadd45a growth arrest and DNA damage 
inducible
NM_007836 1.66 0.0003 1.20 0.2245 -1.24 0.4200 0.0000
Por NADPH cytochrome p450 
oxidoreductase
NM_008898 1.66 0.0806 1.22 0.3847 1.04 0.9392 0.0402
Tieg1 TGFB inducible early growth 
response 1
NM_013692 -1.64 0.0011 -1.23 0.1983 -1.21 0.5440 0.0062
Gstm1 glutathione S-transferase mu 1 NM_010358 1.63 0.2258 -1.14 0.6339 -1.03 0.9622 0.0377
sult1c2 sulfotransferase family 1C, 
member 2
NM_026935 1.55 0.0044 1.16 0.3501 1.21 0.5440 0.0350
AhR rat Ah receptor NM_013464 1.48 0.0423 -1.05 0.7919 -1.12 0.7389 0.0039
Chk choline kinase NM_013490 -1.45 0.0041 -1.31 0.0876 1.02 0.9443 0.0039
Adcy6 adenylate cyclase 6 NM_007405 -1.43 0.0003 -1.20 0.1165 -1.05 0.7925 0.0004
Bhmt betaine homocysteine methyl 
transferase
NM_016668 -1.40 0.2598 -1.16 0.4362 1.19 0.6392 0.0385
gstm2 glutathione S-transferase, mu 2 NM_008183 1.39 0.0313 -1.10 0.4647 -1.01 0.9754 0.0054
Dusp6 dual specificity phosphatase 6 NM_026268 1.39 0.0852 1.23 0.2007 -1.07 0.8288 0.0181
Lbp Lipopolysaccharide binding protein NM_008489 1.39 0.0104 1.15 0.2591 1.32 0.1249 0.0379
Rbp1 retinol binding protein 1, cellular NM_011254 1.34 0.2364 -1.19 0.2941 1.00 0.9976 0.0101
Ephx1 epoxide hydrolase 1, microsomal; 
Eph1, Eph-1, AI195553
NM_010145 1.33 0.0486 -1.08 0.5597 1.05 0.8358 0.0181
Gsta4 Glutathione S-transferase, alpha 4 NM_010357 1.32 0.1312 -1.14 0.3506 -1.10 0.7389 0.0045
Ube2b ubiquitin conjugating enzyme, E2B 
(RAD 6 homoly S.cerevisea)
NM_009458 -1.23 0.0358 -1.01 0.8808 1.00 0.9935 0.0350
Copeb core promoter element binding 
protein
NM_011803 -1.21 0.8557 -1.28 0.1810 -1.44 0.1569 0.0471
Hao1 hydroxyacid oxidase NM_010403 -1.20 0.8890 1.12 0.5641 1.38 0.4200 0.0402
Anpep aminopeptidase N NM_008486 1.20 0.4022 -1.20 0.1456 -1.05 0.8153 0.0070
Egfr epidermal growth factor receptor NM_007912 -1.18 0.7714 -1.04 0.7719 1.21 0.4200 0.0429
Gpam glycerol-3-phosphate 
acyltransferase, mitochondrial
NM_008149 -1.16 0.2258 -1.00 0.9864 1.13 0.4200 0.0068
Olfr1161 olfactory receptor 1161 NM_146848 1.13 0.8471 1.30 0.0420 1.27 0.1191 0.0300
Keap1 Kelch-like ECH-assoc. protein 1, 
cytosolic inhibitor of NRF2)
NM_016679 -1.12 0.8821 -1.24 0.1165 -1.38 0.0941 0.0181
Ssrp1 Structure specific recognition 
protein 1
XM_130271 -1.10 0.8932 -1.13 0.3501 -1.34 0.1191 0.0121
mpg N-methylpurine-DNA glycosylase NM_010822 1.09 0.8894 1.30 0.0420 1.07 0.7269 0.0417
Ape2 AP endonuclease 2 NM_029943 -1.04 0.9530 -1.04 0.8232 -1.37 0.3673 0.0385
Ripk1 receptor (TNFRSF)-interacting 
serine-threonine kinase 1
NM_009068 -1.03 0.9565 -1.10 0.5255 -1.43 0.1191 0.0490
Nme2 expressed in non-metastatic cells 2, 
protein
NM_008705 1.02 0.9737 -1.24 0.2245 -1.12 0.7406 0.0238
Vegfb(2) vascular endothelial growth factor B NM_011697 -1.00 0.9944 -1.21 0.1279 -1.32 0.1191 0.0080
* Data ordered by fold-change in 100 mg/ml dose. There were no significant genes in 0.1 mg/ml dose. † Overall treatment effectBMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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Gadd45b, Gadd45a, Lpin1, Por). However, several other
genes identified in common by the 4-spot analysis were
partitioned into one of the two single-spot analyses: four
of eight genes specific to the non-EC single-spot normali-
zation (Gsta4, Rbp1, gstm2, Ephx1) and two of five genes
specific to the single-spot EC normalization (Rbp1, AhR).
Thus, approximately half of the genes found in common
from the 4-spot analyses were found by either single spot
analysis. Smaller proportions of genes specific to either
normalization in the 4-spot analysis were found to be dif-
ferential by the single spot analyses: 2/15 for non-EC
(Gsta2 Ugt1a6) and 2/11 for EC (Keap1, Bhmt). One gene
specific to the single-spot EC normalization and two
genes specific to the single-spot non-EC normalization
were not identified by the respective 4-spot analyses,
reducing the proportion of genes found by the single spot
analyses to 0.34 and 0.36 for EC and non-EC, respectively,
in this comparison of spot replication effect.
Discussion
Appropriate quality controls and protocols for assessment
of printing and hybridization in microarray experiments
are crucial for ensuring high-quality data and establishing
performance standards. Despite this, controls used for
specifically addressing these issues are rarely reported in
microarray publications. In addition, the development of
features for normalization within, and between arrays is
critical for all microarray applications, and is particularly
relevant to the application of small focused arrays where
a relatively large portion of the pathways may show
changes in gene expression.
We developed an EC dilution series using the spike-in of
a single Arabidopsis chlorophyll synthase gene hybridized
to a series of dilutions of the complementary oligonucle-
otide printed on the microarray. In contrast with other
external spike-in procedures that use a mixture of varying
amounts of different control RNAs spiked into total RNA
to derive signals across a range of intensities (e.g., [4]), our
approach maintains a constant single input of external
RNA, while varying the dilution of the EC oligonucleotide
on the slide itself. This simple and flexible method allows
a more robust quantitation of the spike-in compared to
other methods. In addition, the EC series was designed to
cover the full range of signal intensities (with no gaps)
over the ToxArray™, reaching both background and satu-
rated intensities (Figures 3, 4 and 5). The array incorpo-
rates a design that allows the use of the ECs, in
combination with negative control spots, for detection of
several technical problems that may arise in the printing,
hybridization or scanning of a microarray, permitting cor-
rection or exclusion during subsequent analyses. Differen-
tial intensities of dye fluorescence on microarrays may
arise from factors related to physical or chemical proper-
ties, differences in the efficiency of incorporation during
probe synthesis and as a result of variations in scanner
operation. These EC features can be applied in combina-
tion with LOWESS to normalize such systematic effects.
Dye bias due to differential hybridization that, in part,
may result from concentration-dependent effects within
or between target cRNA populations and array spots that
might arise during hybridization and washing procedures,
may also be subject to this type of normalization. In this
regard, it has been shown that tethered nucleic acid
probes can behave differently depending on the nature of
their supports [13], but here it was shown that the hybrid-
ization pattern derived from dilution of the EC oligonu-
cleotide on the ToxArray™ slide surface was a close mimic
of the pattern of hybridization resulting from similar dilu-
tions of labeled cRNA in solution. A close relationship
between these two concentration vs. intensity curves per-
mits subsequent normalization adjustments of variations
in murine cRNA hybridization intensity ratios, without
introducing large errors. Composite LOWESS adjustments
across the range of EC intensities on each array would be
likely to represent similar differences in concentration-
dependent hybridization amounts of murine genes,
across samples.
Subtle unequal hybridization resulting in spatial pattern-
ing in dye fluorescence across an array might be undetec-
ted by visually examining the arrays, but may be revealed
by the presence of increased variances of Cy3/Cy5 ratios
among the 48 EC replicates and four gene replicates of
each grid. EC features might also be used to control posi-
tional and slide-to-slide hybridization effects that are
more erratic, such as those resulting from exclusion by
bubbles, by taking an average of the ECs within a subgrid,
dividing each spot within the subgrid by the EC average,
followed by multiplication of each spot by an overall slide
average using the external controls. This would be done
for each channel separately. Further refinements in nor-
malization can be envisioned that would employ
attributes of the EC hybridization curve, other than its
average value. A systematic examination of these alternate
approaches has not yet been made.
The limited sequence homology of the A. thaliana oligo-
nucleotide among the genomes of organisms with pub-
lished sequence information, suggests possible
applications to gene expression studies in a wide variety of
organisms. Since oligonucleotide probes designed with
constraints on length, G+C% and secondary structure pro-
duce similar, parallel hybridization values over large
cRNA concentration ranges [14], the choice of oligonucle-
otide used to produce an EC series in the manner we have
described is not necessarily restricted to the sequence
employed in the present experiments.BMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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The placement of negative control features within the Tox-
Array™ design is an innovative approach to allow for the
evaluation of cross-spot contamination during the print-
ing process. Negative controls following either a saturated
signal or a buffer spot were used to demonstrate the carry-
over of oligonucleotides within print-tip groups in a print-
run (Figure 9) (this is a frequent problem in microarray
printing that is rarely mentioned or quantified) [15].
Carry-over can significantly impact analysis of differential
expression if low intensity spots are printed following
spots that vary in intensity and occasionally show high
signals. Similarly, carryover effects would degrade the use-
fulness of the EC series. Each print-run should be evalu-
ated to ensure that this effect is minimized, especially with
the (demonstrated) high fractional sensitivity of the Tox-
array™ (1/2,000,000 transcripts). The knowledge of cross-
spot contamination could be incorporated into the selec-
tion of genes for RT-PCR confirmation and final analysis
of differential gene expression, or print tip groups with
unacceptable levels could be removed from the analysis.
Lastly, the ToxArray™ incorporates 4 replicates of each oli-
gonucleotide spot distributed into separate subgrids on
each slide. This degree and placement of spot replication
can significantly increase the reliability of fluorescence
measurements of gene expression levels [11,16] and
would thereby decrease variability of two-color ratios.
Indeed, fewer genes were identified as differentially
expressed based upon single oligonucleotide spots as
compared to the four replicates in this study.
We exposed mice to a known hepatotoxin to test the
hypothesis that global normalization approaches for
focused microarrays will generate a higher proportion of
false findings, relative to an approach using external fea-
tures. Composite normalization incorporating the EC fea-
tures (described in methods) resulted in a list of 36 genes
with adjusted p-values less than 0.05. The predominant
pathways represented among the genes that were differen-
tially expressed included stress response, growth differen-
tiation, apoptosis and xenobiotic metabolism. Among the
latter, cyp2b10, cyp2b9, Gsta2 and Ephx1 were validated
by RT-PCR. The induction of these pathways is consistent
with the known pathologic effects of PB. This response
was employed to provide confirmation, when verified by
RT-PCR, that the composite normalization would score
higher, as expected, on all measures of effectiveness, com-
pared to the global normalization approach.
We expect the composite normalization to be even more
superior in experiments where larger portions of genes are
responsive. Although PB was an effective modifier of gene
expression in this study of murine liver, only about 40
genes of the total 1600 on ToxArray™ might have been cat-
egorized by RT-PCR as significant responders, predicting
from the existing microarray data and the observed fre-
quencies of RT-PCR confirmation. This was a small pro-
portion (2.5%) of genes represented on the array.
Increased numbers of responding genes might have been
expected, given higher PB doses or a longer treatment
period.
The relatively greater effectiveness of the EC composite
normalization approach has also been found in a comple-
mentary study examining murine liver response to poly-
chlorinated biphenyl exposure, in which 22 genes were
validated using RT-PCR (data not shown – to be pub-
lished elsewhere). The summary statistics presented in
this study should be interpreted with care as there was
some potential for selection bias in the choices made for
RT-PCR validation among the genes identified as differen-
tial by both normalization procedures. However, we are
currently carrying out additional RT-PCR experiments
with other microarray datasets to achieve more represent-
ative estimates.
Conclusion
We demonstrate the application of a simple external con-
trol dilution series, in combination with a novel DNA
array design, to yield improved detection of differential
gene expression and provide quality control measures.
The appropriate placement of controls and replication of
probe spots allows for quantification of positional hybrid-
ization effects and cross-spot contamination. The applica-
tion of a composite normalization, which incorporates an
external control dilution series, results in an improvement
in the sensitivity and predictivity of the test, as well as a
minimization in false positive detection. Dilution of oli-
gonucleotides on the microarray itself provides an inno-
vative approach allowing the full dynamic range of the
scanner to be covered with a single gene spike-in.
Methods
ToxArray™ gene selection
The list of ToxArray™ genes was compiled from our own
data, as well as extensive information from published
studies investigating gene expression changes, assessed
using microarrays or other technologies, following toxi-
cant exposures. Mouse genes (and homologues of rat and
human genes) shown to be useful in toxicant-specific pro-
filing were included [4,17-19]. Additionally, a large frac-
tion of murine genes known to be involved in DNA repair,
as well as the mouse cytochrome p450 family, were
included. Our current list includes approximately 1600
genes known to respond to a wide range of toxic stressors.
Approximately 50 housekeeping genes have been
included on the array. Single-stranded 5'-C6 amino mod-
ified 70 mer oligonucleotide probes were designed and
synthesized by Qiagen Inc (Alameda, CA, USA).BMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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Table 2: ToxArray™ data normalized without EC: Overall adjusted p after exposure to PB and fold changes (relative to Control) and 
pairwise p-values at each dose for each gene (probe) that showed differential expression. Bold text indicates genes identified as 
differential overall (p < 0.05) in the EC-normalized analysis (Table 1).
Control versus 
100 mg/kg
Control versus 
10 mg/kg
Control versus 
1 mg/kg
James-Stein 
F-Test
Gene 
(probe) 
Name
Full name GenBank Fold 
change
Pairwise 
P-value
Fold 
change
Pairwise 
P-value
Fold 
change
Pairwise 
P-value
Overall
 P-value
Cyp2b9* cytochrome P450, 2b9, 
phenobarbitol inducible, type a, 
NM_010000 8.55 0.0000 3.56 0.0000 1.15 0.8412 0.0000
Cyp2b10 Cytochrome P450, 2b10, 
phenobarbitol inducible, type b
NM_009998 3.93 0.0000 2.92 0.0000 -1.08 0.8501 0.0000
Gdf15 growth differentiation factor 15 NM_011819 2.57 0.0000 1.26 0.6381 1.11 0.8311 0.0002
Gsta2 Glutathione S-transferase, alpha 2 (Yc2) NM_008182 2.26 0.0353 1.08 0.9165 -1.22 0.7337 0.0160
Gstm3 glutathione S- transferase mu 3 
(EC 2.5.1.18) 
J03953 2.21 0.0000 -1.01 0.9793 1.31 0.4323 0.0002
Gadd45b growth arrest and DNA-damage-
inducible 45 beta
NM_008655 1.93 0.0000 1.04 0.8931 -1.12 0.6016 0.0000
Lpin1 lipin 1, alias fatty liver dystrophy NM_015763 -1.66 0.0037 -1.02 0.9469 1.03 0.9303 0.0051
Gadd45a growth arrest and DNA damage 
inducible
NM_007836 1.62 0.0024 1.25 0.4642 -1.22 0.4506 0.0000
Idi1 isopentenyl-diphosphate delta isomerase NM_145360 -1.57 0.0131 -1.44 0.2098 -1.04 0.9206 0.0160
Por NADPH cytochrome p450 
oxidoreductase
NM_008898 1.55 0.0489 1.34 0.4157 1.07 0.8477 0.0341
Rbp1 retinol binding protein 1, cellular NM_011254 1.49 0.0029 1.04 0.8850 1.14 0.5150 0.0094
AhR rat Ah receptor NM_013464 1.42 0.0676 1.06 0.8713 -1.07 0.8304 0.0436
Dusp6 dual specificity phosphatase 6  NM_026268 1.41 0.0486 1.29 0.3460 -1.04 0.9018 0.0107
Gsta4 Glutathione S-transferase, alpha 4 NM_010357 1.41 0.0037 -1.00 0.9961 -1.09 0.6389 0.0006
gstm2 glutathione S-transferase, mu 2 NM_008183 1.40 0.0131 1.05 0.8594 1.07 0.7447 0.0329
Ephx1 epoxide hydrolase 1, microsomal; 
Eph1, Eph-1, AI195553
NM_010145 1.39 0.0004 1.08 0.6873 1.11 0.4882 0.0021
Chk choline kinase NM_013490 -1.39 0.0214 -1.17 0.5202 1.03 0.9165 0.0223
Ugt1a6 UDP glycosyltransferase 1 family, 
polypeptide A6
XM_135531 1.38 0.0019 1.22 0.2979 1.13 0.4624 0.0063
Lbp Lipopolysaccharide binding protein NM_008489 1.38 0.0254 1.12 0.6547 1.35 0.1677 0.0436
Adcy6 adenylate cyclase 6 NM_007405 -1.34 0.0037 -1.04 0.8511 1.01 0.9774 0.0068
Pitpn phosphatidylinositol transfer protein NM_008850 1.23 0.0000 1.07 0.4947 1.08 0.4311 0.0004
Olfr447 olfactory receptor 447 NM_146988 -1.20 0.6328 -1.19 0.4947 1.03 0.9112 0.0436
Anpep aminopeptidase N NM_008486 1.20 0.3851 -1.14 0.5202 -1.02 0.9253 0.0223
cd8b CD8 antigen, beta chain NM_009858 -1.16 0.0158 -1.07 0.5160 -1.11 0.2616 0.0436
Cyp2a4 Cytochrome P450, 2a4 
(phenobarbitol inducer
NM_009997 1.14 0.3851 -1.07 0.6474 -1.09 0.4999 0.0045
Mmp9: matrix metalloproteinase 9 NM_013599 -1.14 0.0735 -1.15 0.1425 -1.16 0.1632 0.0305
Egfr epidermal growth factor receptor NM_007912 -1.13 0.9847 1.07 0.8206 1.30 0.1971 0.0192
Hao1 hydroxyacid oxidase NM_010403 -1.12 0.9867 1.24 0.5202 1.42 0.1991 0.0233
Gpam glycerol-3-phosphate 
acyltransferase, mitochondrial
NM_008149 -1.10 0.9847 1.11 0.5202 1.20 0.1971 0.0063
Ape2 AP endonuclease 2 NM_029943 -1.09 0.9867 -1.18 0.5833 -1.43 0.1677 0.0395
Acadvl acyl-Coenzyme A dehydrogenase, 
very long chain
NM_017366 -1.07 0.9867 1.10 0.5887 1.18 0.2294 0.0436
SCADfami
lyprotein
mRNA for SCAD family protein AJ296079 -1.05 0.9890 1.02 0.9388 1.26 0.1971 0.0395
PERP PERP, TP53 apoptosis effector NM_022032 -1.04 0.9890 1.06 0.7161 1.15 0.2892 0.0170
Acaa2 acetyl-Coenzyme A acyltransferase 2, 
mitochondrial
NM_177470 -1.02 0.9984 1.11 0.5202 1.24 0.1632 0.0094
Vegfb(2) vascular endothelial growth factor B NM_011697 -1.02 0.9984 -1.25 0.2731 -1.31 0.1677 0.0101
Fads2 fatty acid desaturase 2 NM_019699 -1.02 0.9984 1.22 0.3816 1.29 0.1902 0.0395
Nme2 expressed in non-metastatic cells 2, 
protein
NM_008705 1.01 0.9984 -1.21 0.4947 -1.14 0.5423 0.0436
Pxmp3 peroxisomal membrane protein 3 NM_008994 -1.01 0.9984 1.11 0.3446 1.14 0.1677 0.0242
Unc5h3 Unc5c:unc-5 homolog C (C. elegans), 
rostral cerebellar malform.
NM_009472 -1.00 0.9984 -1.08 0.6381 1.03 0.8466 0.0475
* Bolded text indicates genes also identified as differential in the EC-normalized analysis (Table 1)B
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Table 3: Real-time RT-PCR analysis of significant genes (p < 0.05) identified in microarray data normalized with and/or without EC dilution series.
Name Full Name GenBank Overall Treatment Effect Pairwise Comparisons
With EC Without EC # of Flagged Spots With EC Without EC RT-PCR
p-value p-value Sample Ref. Comparison foldchange p-value foldchange p-value foldchange p-value
Differentially expressed using both the EC and non-EC normalization
Adcy6 adenylate cyclase 6 NM_007405 0.0004 0.0068 6 0 100 mg/kg -1.43 0.0003 -1.34 0.0037
Chk choline kinase NM_013490 0.0039 0.0223 1 0 100 mg/kg -1.45 0.0041 -1.39 0.0214 -2.39 0.0122
Cyp2b10 Cytochrome P450, 2b10, 
phenobarbitol inducible, type b
NM_009998 0.0000 0.0000 8 20 100 mg/kg 5.10 0.0000 3.93 0.0000 3.76 0.0001
Cyp2b10 NM_009998 10 mg/kg 2.95 0.0000 2.92 0.0000 1.04 0.8600
Cyp2b9 cytochrome P450, 2b9, phenobarbitol 
inducible, type a
NM_010000 0.0000 0.0000 15 22 100 mg/kg 8.29 0.0000 8.55 0.0000 3.04 0.0965
Cyp2b9 NM_010000 10 mg/kg 3.22 0.0000 3.56 0.0000 2.74 0.0052
Ephx1 epoxide hydrolase 1, microsomal; 
Eph1, Eph-1, AI195553
NM_010145 0.0181 0.0021 0 0 100 mg/kg 1.33 0.0486 1.39 0.0004 1.46 0.0350
Gadd45a growth arrest and DNA damage 
inducible
NM_007836 0.0000 0.0000 17 0 100 mg/kg 1.66 0.0003 1.62 0.0024
Gadd45b growth arrest and DNA-damage-
inducible 45 beta
NM_008655 0.0000 0.0000 25 1 100 mg/kg 1.92 0.0000 1.93 0.0000
Gdf15 growth differentiation factor 15 NM_011819 0.0000 0.0002 10 1 100 mg/kg 2.83 0.0000 2.57 0.0000
gstm2 glutathione S-transferase, mu 2 NM_008183 0.0054 0.0002 0 0 100 mg/kg 1.39 0.0313 1.40 0.0000 1.50 0.0013
Gstm3 glutathione S-transferase, mu 3 J03953 0.0000 0.0160 6 24 100 mg/kg 2.16 0.0000 2.21 0.0131
Lbp Lipopolysaccharide binding protein NM_008489 0.0379 0.0051 1 25 100 mg/kg 1.39 0.0104 1.38 0.0037 1.60 0.0345
Lpin1 lipin 1 NM_015763 0.0039 0.0037 0 3 100 mg/kg -1.94 0.0009 -1.66 0.0037
Differentially expressed using EC normalization only
AhR rat Ah receptor NM_013464 0.0039 0.0436 0 0 100 mg/kg 1.48 0.0423 1.42 0.0676 2.03 0.0003
Mpg N-methylpurine-DNA glycosylase NM_010822 0.041698 0.3782 25 25 10 mg/kg 1.30 0.0420 1.13 0.3911 1.42 0.0096
Olfr1161 olfactory receptor 1161 NM_146848 0.03003 0.0800 25 25 10 mg/kg 1.30 0.0420 1.12 0.3921 1.02 0.9618
sult1c2 sulfotransferase family 1C, member 2 NM_026935 0.0350 0.0572 18 25 100 mg/kg 1.55 0.0044 1.56 0.0214 1.60 0.0161B
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Tieg1 TGFB inducible early growth 
response 1
NM_013692 0.0062 0.1318 0 0 100 mg/kg -1.64 0.0011 -1.45 0.0627 -2.88 0.0008
Ube2b ubiquitin conjugating enzyme NM_009458 0.0350 0.0897 0 0 100 mg/kg -1.23 0.0358 -1.16 0.7402 -1.56 0.0058
Differentially expressed using non-EC normalization only
cd8b CD8 antigen, beta chain NM_009858 0.2327 0.0436 25 25 100 mg/kg -1.10 0.8557 -1.16 0.0158 1.40 0.3272
Dusp6 dual specificity phosphatase 6 NM_026268 0.0181 0.0107 16 0 100 mg/kg 1.39 0.0852 1.41 0.0486 1.40 0.0752
Gsta2 Glutathione S-transferase, alpha 2 
(Yc2)
NM_008182 0.0681 0.0160 0 0 100 mg/kg 1.84 0.2849 2.26 0.0353 4.02 0.0026
Gsta4 Glutathione S-transferase, alpha 4 NM_010357 0.0045 0.0006 4 4 100 mg/kg 1.32 0.1312 1.41 0.0037 1.20 0.2200
Idi1 isopentenyl-diphosphate delta 
isomerase
NM_145360 0.0835 0.0436 0 0 100 mg/kg -1.58 0.1234 -1.57 0.0254 -1.16 0.3523
Pitpn phosphatidylinositol transfer protein NM_008850 0.0969 0.0004 20 15 100 mg/kg 1.24 0.0624 1.23 0.0000 1.07 0.3100
Por NADPH cytochrome p450 
oxidoreductase
NM_008898 0.0402 0.0341 0 0 100 mg/kg 1.66 0.0806 1.55 0.0489 1.45 0.0064
Rbp1 retinol binding protein 1, cellular NM_011254 0.0101 0.0094 0 7 100 mg/kg 1.34 0.2364 1.49 0.0029 1.13 0.3600
Ugt1a6 UDP glycosyltransferase 1 family, 
polypeptide A6
XM_135531 0.0942 0.0063 0 0 100 mg/kg 1.35 0.1044 1.38 0.0019 -1.06 0.4810
Not differentially expressed
Anpep aminopeptidase N NM_008486 0.0070 0.0223 5 9 100 mg/kg 1.20 0.4022 1.20 0.3851
Anpep NM_008486 10 mg/kg -1.20 0.1456 -1.14 0.9253 -1.04 0.6932
Cyp2a4 Cytochrome P450, 2a4 
(phenobarbitol inducer)
NM_009997 0.0818 0.0045 24 24 100 mg/kg 1.19 0.2364 1.14 0.3851
Cyp2a4 NM_009997 10 mg/kg 1.12 0.2511 -1.07 0.4999 1.32 0.0789
mpg N-methylpurine-DNA glycosylase NM_010822 0.0417 0.3782 25 25 100 mg/kg 1.09 0.8894 1.03 0.9890 -1.15 0.1757
Olfr1161 olfactory receptor 1161 NM_146848 0.0300 0.0800 25 25 100 mg/kg 1.13 0.8471 1.06 0.9867 -2.87 0.0386
Table 3: Real-time RT-PCR analysis of significant genes (p < 0.05) identified in microarray data normalized with and/or without EC dilution series. (Continued)BMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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ToxArray™ Design
The ToxArray™ consists of 12 sub-grids (16 rows × 12 col-
umns) printed in quadruplicate (for a total of 48 sub-
grids). External control (EC) normalization features are
present in every sub-grid and consist of a series of 18 dilu-
tions of a single probe corresponding to the Arabidopsis
thaliana chlorophyll synthase gene (RefSeq NM_115041).
The dilution series of the probe is prepared in ArrayIT
spotting solution (Telechem International, Sunnyvale,
CA, USA) (concentrations range from 0.000015 µM to
100 µM). Each EC probe dilution is printed at least twice
per sub-grid (42 EC features per sub-grid) for a total of
more than 2000 EC features across the space of the entire
array. Each sub-grid also contains three types of negative
controls including: buffer-only spots, randomized pools
of non-specific 70 mer oligonucleotides (Qiagen Inc.; val-
idated to ensure that they do not match any known mouse
genes), and random hexamers (Qiagen, Inc.) in ArrayIT
Table 4: Criteria for determination of the true positives (TP), false negatives (FN), false positives (FP) and true negatives (TN) for the 
microarray results.
Microarray Result using the Fs-test
Positive Negative
Overall Treatment Effect FDR p-value < 0.05 FDR p-value > 0.05
AND OR
Pairwise Comparison with Control* FDR p-value < 0.05 FDR p-value > 0.05
RT PCR Result
p-value < 0.05 (differentially expressed) TP FN
p-value > 0.05 (no change) FP TN
* comparison of individual doses against the control
Table 5: Measures of performance of microarray findings using normalization incorporating the external control features, compared 
to not incorporating the external control features.
A. Using all microarray pairwise comparisons
Microarray result using EC Normalization Microarray result NOT using EC normalization
RT-PCR result: Significant Not Significant Significant Not Significant
Significant 11 a 3b 8a 9b
Not Significant 3c 10d 6c 4d
Sensitivity 78.6% 57.1%
Specificity 76.9% 30.8%
Positive Predictive Value 78.6% 47.1%
Negative Predictive Value 76.9% 40.0%
Efficiency of the test 77.8% 44.4%
B. Using microarray pairwise comparisons that were in disagreement
Microarray result using EC Normalization Microarray result NOT using EC normalization
RT-PCR result: Significant Not Significant Significant Not Significant
Significant 5 a 1b 2a 7b
Not Significant 3c 10d 6c 4d
Sensitivity 62.5% 25.0%
Specificity 90.9% 36.4%
Positive Predictive Value 83.3% 22.2%
Negative Predictive Value 76.9% 40.0%
Efficiency of the test 79.0% 31.6%
Sensitivity= TP/(TP+FN); Specificity = TN/(TN+FP); Pos. Predictive Value= TP/(TP+FP); Neg. Predictive Value = TN/(TN+FN); Efficiency = 
(TP+TN)/(TP+TN+FP+FN).
a True Positive; b False Negative; c False Positive; d True NegativeBMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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buffer (Figure 1). The latter two negative controls are use-
ful to detect background resulting from fluorescence sig-
nal from oligonucleotides or random non-specific
binding. Within each sub-grid, placement of one buffer
control (Spots C; Figure 1) immediately follows the print-
ing of a 100 µM EC oligonucleotide (Spots B; Figure 1).
The 100 µM signal reaches saturation; juxtaposition of the
buffer control spot immediately following the saturated
control allows the calculation of cross-spot contamina-
tion, or carry-over of oligonucleotides across individual
spots by the printing pin. Cross-spot contamination was
evaluated by comparing the signal from spots C, to a
buffer-only spot within the same sub-grid that is printed
immediately following another buffer-only spot (Spot A;
Figure 1).
A 70 mer oligonucleotide probe was designed and synthe-
sized for the Arabidopsis thaliana chlorophyll synthase
gene (At3g51820; RefSeq NM_115041) (Qiagen Inc.,
Alameda, CA, USA). A. thaliana chlorophyll synthase RNA
was produced through in vitro transcription of a plasmid
provided by the University Health Network Microarray
Centre (Toronto, ON, CA) (the plasmid contains a frag-
ment of the A. thaliana chlorophyll synthase gene) using
the T7 RiboMAX™ Express Large Scale RNA Production
System according to manufacturers protocol (Promega
Corporation, Madison, WI, USA). In vitro transcribed RNA
was quantified by UV light absorbance and visualized for
transcript integrity by gel electrophoresis.
ToxArray™ Production
Oligonucleotides were diluted in ArrayIT Spotting Solu-
tion (Telechem International) to 40 µM and printed onto
PowerMatrix slides (Full Moon Biosystems, Sunnyvale,
CA, USA) with the ChipWriter Pro robotic arrayer (BioRad
Laboratories, Mississauga, ON, CA) at 65% relative
humidity. Printing pins were washed in water, dried, and
sonicated in water three times between each pin loading.
Following printing, slides were placed in a humid cham-
ber, containing saturated sodium chloride solution, with
a relative humidity of 65–75% for 10–14 hours. Slides
were air dried at room temperature for 30 minutes. Prior
to hybridization slides were pretreated according to man-
ufacturer's protocol (Full Moon Biosystems). Briefly,
slides were incubated at room temperature in 0.2X SSC
solution containing 0.2% SDS and 0.1% BSA, preheated
to 55°C for 15–30 minutes on an orbital shaker, rinsed
thoroughly in Milli-Q water, and dried by centrifugation
at 500 rpm for 5 minutes.
Animal Treatment
Male B6C3F1 mice (age 27–35 days) obtained from
Charles River were allowed food and water ad libitum. The
animals were housed in individual cages under a 12 hr
light/12 hr dark lighting schedule, constant temperature
and humidity, and provided with an enriched environ-
ment. Animals were acclimatized for at least 2 weeks.
Treatment groups consisted of 5 animals dosed by oral
gavage with 100, 10, 1 or 0.1 mg/kg Phenobarbital (PB)
(CAS: 57-30-7) or 0.9% saline (vehicle control group) for
3 consecutive days. Animals were sacrificed four hours
after the last PB exposure. Animals were anesthetized with
CO2, 0.5–0.7 mL of blood was collected by cardiac punc-
ture, and animals were sacrificed by cervical dislocation.
Liver was removed, flash-frozen in liquid nitrogen, and
stored at -80°C for further analyses. All animal care and
handling were in accordance with Canadian Council for
Animal Care Guidelines and were reviewed by the Health
Canada Animal Care Committee prior to the start of the
study.
RNA isolation
Total RNA from mouse liver was isolated using Trizol Rea-
gent (Gibco-BRL, Life Technologies, Gaithersburg, Mary-
land, USA) according to the manufacturer's protocol.
Briefly, 1 mL of Trizol reagent was added per 50–100 mg
tissue and homogenized. Homogenized samples were
incubated for 5 minutes at room temperature; chloroform
was added at 0.2 mL per 1 mL Trizol reagent, mixed by
inversion and incubated for 3 minutes. The aqueous
phase was separated by centrifugation, and RNA was pre-
cipitated by the addition of isopropanol at 0.5 mL per 1
mL Trizol reagent and incubation for 10 minutes at room
temperature. RNA was washed in 75% ethanol and re-dis-
solved in 1 µL nuclease-free water per 1 mg of tissue. Total
RNA was further purified using the RNeasy Mini Kit (Qia-
gen Inc.) according to the manufacturer's protocol. RNA
quality and quantity was assessed by UV spectrophotom-
etry and 28S:18S ratios obtained by Agilent 2100 bioana-
lyzer (Agilent Technologies, Palo Alto, CA, USA).
Preparation of labeled cRNA
Labeled cRNA was prepared using the Low Input Fluores-
cent Linear Amplification Kit from Agilent Technologies
according to manufacturer's protocol. For analysis of dif-
ferential expression following PB exposures, 5 ng of EC
RNA was spiked into 5 µg of liver RNA sample and mouse
reference RNA (Stratagene, La Jolla, CA, USA). RNA was
converted to cDNA using oligo dT-T7 promoter primer
and random hexamers. Following second strand cDNA
synthesis, cDNA was converted to cRNA and amplified by
T7 RNA polymerase in the presence of Cy5- (liver cDNA)
or Cy3-CTP (reference cDNA). The amplified cRNA prod-
uct was purified using the RNeasy Mini Kit (Qiagen, Inc.),
re-suspended in nuclease-free water, and quantified by UV
spectrophotometry.
Automated Hybridization Protocol
Automated microarray hybridizations were carried out in
an HS 4800 hybridization station (TECAN, Research Tri-BMC Genomics 2006, 7:266 http://www.biomedcentral.com/1471-2164/7/266
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angle Park, NC, USA). Microarrays were pre-washed two
times (50°C, 30 minutes; 0.2× SSC, 0.2% SDS, 0.1%
BSA). Fifteen µg of labeled Cy5 and Cy3 cRNA probe was
fragmented in 25× fragmentation buffer (Agilent In situ
hybridization kit-plus, Agilent Technologies) at 60°C for
30 minutes. Fragmented cRNA was mixed with 2× hybrid-
ization buffer (Agilent In situ hybridization kit-plus) and
hybridized on the ToxArray™ chips at 60°C for 17 h.
Chips were washed with 6 × SSC, 0.005% Triton X-102 at
50°C for 10 min, with 0.1× SSC, 0.005% Triton X-102 at
room temperature for 15 min, and rinsed with 0.06× SSC.
Microarrays were dried by centrifugation at 500 rpm for 5
minutes. For PB experiments, sample RNA was labeled
with Cy5 and Universal mouse RNA was labeled with Cy3
and the automated procedure was used for hybridization
and washing of all slides.
Real time PCR
RT-PCR was used to confirm differential gene expression
of transcripts from microarray analyses. Reverse transcrip-
tion was carried out in a 100 µl reaction mix with Super-
Script II (Invitrogen, Burlington, ON, CA) using 1 µg total
RNA per animal. Quantitative PCR was performed with an
iCycler IQ real-time detection system (BioRad Laborato-
ries) using SYBR-Green. Using 1 µl reverse transcription
solution and gene-specific primers (Qiagen, Mississauga,
ON, Canada), PCR was performed in a 25 µl reaction
Supermix (BioRad Laboratories). Primers were designed
using Beacon design 2.0 (Premier BioSoft International,
CA, USA) and sequences are available upon request. PCR
reactions for each RNA species were performed in dupli-
cate within a single plate, and the values of threshold cycle
were averaged. Gene expression levels were normalized to
β2-microglobulin, which was found to be stable on the
DNA microarrays. PCR efficiency was examined using the
standard curve for each gene, determined from reactions
that were included in wells of the respective plate. Primer
specificity was assured by the melting curve for each gene.
A t-test was used for statistical evaluation.
Image analysis and statistics
Arrays were scanned on a ScanArray Express (Perkin Elmer
Life Sciences, Woodbridge, ON, Canada). To optimize the
dynamic range of microarrays and allow the quantifica-
tion of both high and low copy expressed genes, the same
arrays were scanned using different photomultiplier set-
tings allowing selection of images with saturated image
intensities on the 50 and 100 µM EC spots and on oligo-
nucleotide spots for high-abundance genes such as Rpl5.
Raw pixel intensities were derived in ImaGene 5.6 (Bio-
Discovery, Los Angeles, CA) and median signal intensities
(not background subtracted) were used for subsequent
analyses. Obtained data conformed to the suggested aver-
age [log2(Cy3*Cy5)/2 of 10 to 12 (1024 to 4096 RFUs)
[20]. Data is available through ArrayExpress [21]. Present
calls were determined as signals that were greater than the
mean of the random 70 mer oligonucleotide negative
controls plus three times the standard deviation (signals
within the range of three standard deviations were
flagged). Data from all samples were read into SAS 8.2
(SAS Institute Inc, Cary, NC, USA). The data were normal-
ized using the composite LOWESS method [8] which
takes a weighted average from a LOWESS fit using only the
ECs with a span of 0.3, and a second LOWESS fit for each
of the 12 print-tip groups with a span of 0.5. Technical
replicates on arrays were collapsed by use of the median
normalized relative intensity. For comparison, a second
normalization was carried out on PB samples using a
LOWESS with a smooth span of 0.4 without incorpora-
tion of ECs. The MAANOVA 2.0 [22] library in R was used
for graphical displays and analysis. Ratio-intensity plots
for each array were obtained. Higher-level statistical anal-
ysis, including detection of differential expression was
also conducted using MAANOVA methodology [1,23].
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